🇺🇸 Clevidipine butyrate in United States

11 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Oxygen Saturation Decreased — 2 reports (18.18%)
  2. Agitation — 1 report (9.09%)
  3. Atrial Fibrillation — 1 report (9.09%)
  4. Atrial Flutter — 1 report (9.09%)
  5. Atrioventricular Dissociation — 1 report (9.09%)
  6. Blood Pressure Decreased — 1 report (9.09%)
  7. Cardiac Arrest — 1 report (9.09%)
  8. Cardiac Failure Congestive — 1 report (9.09%)
  9. Cardiac Index Decreased — 1 report (9.09%)
  10. Cardio-Respiratory Arrest — 1 report (9.09%)

Source database →

Clevidipine butyrate in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Clevidipine butyrate approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Clevidipine butyrate in United States?

Methodist Healthcare is the originator. The local marketing authorisation holder may differ — check the official source linked above.